File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1517/14656560902980228
- Scopus: eid_2-s2.0-67649690531
- PMID: 19445558
- WOS: WOS:000267235800014
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Bazedoxifene: A new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis
Title | Bazedoxifene: A new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis |
---|---|
Authors | |
Keywords | Bazedoxifene Estrogen Osteoporosis Selective estrogen receptor modulator |
Issue Date | 2009 |
Publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop |
Citation | Expert Opinion On Pharmacotherapy, 2009, v. 10 n. 8, p. 1377-1385 How to Cite? |
Abstract | Bazedoxifene acetate (WAY-140424; TSE-424) is an oral, nonsteroidal, indole-based selective estrogen receptor modulator (SERM) being developed for the prevention and treatment of osteoporosis. Preclinical studies on bazedoxifene have demonstrated estrogen agonist effects on the skeleton and lipid metabolism but not on breast and uterine endometrium. In combination with estrogen, bazedoxifene antagonizes the stimulatory action of estrogens on proliferation of breast cancer cells and endometrium. Phase III clinical studies have shown favorable effects on the skeleton without stimulation of endometrium and breast. Bazedoxifene prevents bone loss in postmenopausal women without osteoporosis and reduces vertebral fractures in women with postmenopausal osteoporosis. In women at high risk of fracture with multiple risk factors, bazedoxifene reduces nonvertebral fracture risk in post-hoc analysis. Bazedoxifene in combination with conjugated estrogens represents a new form of therapeutic agents for the treatment of postmenopausal symptoms and prevention of postmenopausal osteoporosis. Clinical trials with bazedoxifene/conjugated estrogens have shown beneficial effects on bone mineral density and bone turnover markers with improvement in vasomotor symptoms and little or no stimulation of breast and endometrium. © 2009 Informa UK Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/59182 |
ISSN | 2023 Impact Factor: 2.5 2023 SCImago Journal Rankings: 0.687 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kung, AWC | en_HK |
dc.contributor.author | Chu, EYW | en_HK |
dc.contributor.author | Xu, L | en_HK |
dc.date.accessioned | 2010-05-31T03:44:29Z | - |
dc.date.available | 2010-05-31T03:44:29Z | - |
dc.date.issued | 2009 | en_HK |
dc.identifier.citation | Expert Opinion On Pharmacotherapy, 2009, v. 10 n. 8, p. 1377-1385 | en_HK |
dc.identifier.issn | 1465-6566 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/59182 | - |
dc.description.abstract | Bazedoxifene acetate (WAY-140424; TSE-424) is an oral, nonsteroidal, indole-based selective estrogen receptor modulator (SERM) being developed for the prevention and treatment of osteoporosis. Preclinical studies on bazedoxifene have demonstrated estrogen agonist effects on the skeleton and lipid metabolism but not on breast and uterine endometrium. In combination with estrogen, bazedoxifene antagonizes the stimulatory action of estrogens on proliferation of breast cancer cells and endometrium. Phase III clinical studies have shown favorable effects on the skeleton without stimulation of endometrium and breast. Bazedoxifene prevents bone loss in postmenopausal women without osteoporosis and reduces vertebral fractures in women with postmenopausal osteoporosis. In women at high risk of fracture with multiple risk factors, bazedoxifene reduces nonvertebral fracture risk in post-hoc analysis. Bazedoxifene in combination with conjugated estrogens represents a new form of therapeutic agents for the treatment of postmenopausal symptoms and prevention of postmenopausal osteoporosis. Clinical trials with bazedoxifene/conjugated estrogens have shown beneficial effects on bone mineral density and bone turnover markers with improvement in vasomotor symptoms and little or no stimulation of breast and endometrium. © 2009 Informa UK Ltd. All rights reserved. | en_HK |
dc.language | eng | en_HK |
dc.publisher | Informa Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop | en_HK |
dc.relation.ispartof | Expert Opinion on Pharmacotherapy | en_HK |
dc.subject | Bazedoxifene | - |
dc.subject | Estrogen | - |
dc.subject | Osteoporosis | - |
dc.subject | Selective estrogen receptor modulator | - |
dc.subject.mesh | Clinical Trials as Topic | en_HK |
dc.subject.mesh | Humans | en_HK |
dc.subject.mesh | Indoles - therapeutic use | en_HK |
dc.subject.mesh | Osteoporosis, Postmenopausal - drug therapy | en_HK |
dc.subject.mesh | Selective Estrogen Receptor Modulators - therapeutic use | en_HK |
dc.title | Bazedoxifene: A new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Kung, AWC:awckung@hku.hk | en_HK |
dc.identifier.authority | Kung, AWC=rp00368 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1517/14656560902980228 | en_HK |
dc.identifier.pmid | 19445558 | - |
dc.identifier.scopus | eid_2-s2.0-67649690531 | en_HK |
dc.identifier.hkuros | 158951 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-67649690531&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 10 | en_HK |
dc.identifier.issue | 8 | en_HK |
dc.identifier.spage | 1377 | en_HK |
dc.identifier.epage | 1385 | en_HK |
dc.identifier.isi | WOS:000267235800014 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Kung, AWC=7102322339 | en_HK |
dc.identifier.scopusauthorid | Chu, EYW=26666500500 | en_HK |
dc.identifier.scopusauthorid | Xu, L=7404744597 | en_HK |
dc.identifier.citeulike | 4690753 | - |
dc.identifier.issnl | 1465-6566 | - |